QIAGEN Total Assets 2010-2022 | QGEN

QIAGEN total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • QIAGEN total assets for the quarter ending September 30, 2022 were $6.517B, a 7.83% increase year-over-year.
  • QIAGEN total assets for 2021 were $6.147B, a 4.72% increase from 2020.
  • QIAGEN total assets for 2020 were $5.87B, a 12.11% increase from 2019.
  • QIAGEN total assets for 2019 were $5.236B, a 8.92% decline from 2018.
QIAGEN Annual Total Assets
(Millions of US $)
2021 $6,147
2020 $5,870
2019 $5,236
2018 $5,748
2017 $5,039
2016 $4,308
2015 $4,179
2014 $4,454
2013 $4,088
2012 $4,088
2011 $3,730
2010 $3,914
2009 $3,796
QIAGEN Quarterly Total Assets
(Millions of US $)
2022-09-30 $6,517
2022-06-30 $6,154
2022-03-31 $6,184
2021-12-31 $6,147
2021-09-30 $6,043
2021-06-30 $5,907
2021-03-31 $5,763
2020-12-31 $5,870
2020-09-30 $5,771
2020-06-30 $5,295
2020-03-31 $5,181
2019-12-31 $5,236
2019-09-30 $5,143
2019-06-30 $5,383
2019-03-31 $5,420
2018-12-31 $5,748
2018-09-30 $5,299
2018-06-30 $5,309
2018-03-31 $5,105
2017-12-31 $5,039
2017-09-30 $5,097
2017-06-30 $4,556
2017-03-31 $4,068
2016-12-31 $4,308
2016-09-30 $4,328
2016-06-30 $4,119
2016-03-31 $4,120
2015-12-31 $4,179
2015-09-30 $4,159
2015-06-30 $4,131
2015-03-31 $4,170
2014-12-31 $4,454
2014-09-30 $4,461
2014-06-30 $4,564
2014-03-31 $4,487
2013-12-31 $4,088
2013-09-30 $4,055
2013-06-30 $3,976
2013-03-31 $4,034
2012-12-31 $4,088
2012-09-30 $3,956
2012-06-30 $3,877
2012-03-31 $3,798
2011-12-31 $3,730
2011-09-30 $3,948
2011-06-30 $3,998
2011-03-31 $3,958
2010-12-31 $3,914
2010-09-30 $3,891
2010-06-30 $3,768
2010-03-31 $3,780
2009-12-31 $3,796
2009-09-30 $3,755
2009-06-30 $2,971
2009-03-31 $2,832
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.167B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $171.581B 10.47
GSK (GSK) United Kingdom $71.504B 8.96
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.492B 0.00
Myovant Sciences (MYOV) United Kingdom $2.595B 0.00
Arcus Biosciences (RCUS) United States $2.459B 36.91
Biohaven (BHVN) United States $1.112B 0.00
Emergent Biosolutions (EBS) United States $0.588B 4.62
Zymeworks (ZYME) Canada $0.480B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.270B 0.00
Enzo Biochem (ENZ) United States $0.092B 0.00
SQZ Biotechnologies (SQZ) United States $0.042B 0.00
Gelesis Holdings (GLS) United States $0.032B 0.00
Ambrx Biopharma (AMAM) United States $0.020B 0.00